Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

October 01, 2020

Philip W. Kantoff, MD, discusses current approaches for patients with metastatic hormone-sensitive prostate cancer, and nonmetastatic/metastatic castration-resistant prostate cancer who progress on androgen blocking agents.

September 28, 2020

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

September 24, 2020

Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.

September 18, 2020

Connie L. Batlevi, MD, PhD, discusses challenges faced in the treatment of patients with follicular lymphoma.

September 15, 2020

Robert J. Motzer, MD, discusses the phase 3 TIVO-1 trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma.

September 14, 2020

Nearly 15 years have passed since pathologists at Memorial Sloan Kettering Cancer Center conducted gene expression analyses on breast cancer primary tumors and described a potential role for a novel target, which quickly became a major research focus for their colleague Tiffany A. Traina, MD.

September 02, 2020

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.

August 10, 2020

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

August 03, 2020

Patients in New York City with cancer who are then diagnosed with novel coronavirus 2019 (COVID-19) are marked by substantial hospitalization rates and severe outcomes.

June 17, 2020

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

June 17, 2020

Chung-Han Lee, MD, PhD, discusses the efficacy of combining immunotherapy with TKIs to treat patients with metastatic renal cell carcinoma.

June 15, 2020

Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

June 10, 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

June 09, 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

June 05, 2020

Michael J. Morris, MD, discusses the impact of prostate-specific membrane antigen-targeted imaging with 18F-DCFPyL-PET/CT on the clinical management of patients with prostate cancer.

June 05, 2020

Zsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

June 04, 2020

Chung-Han Lee, MD, PhD, discusses the potential for combining TKIs with immunotherapy in patients with metastatic renal cell carcinoma who have progressed on prior checkpoint inhibitors.

May 27, 2020

Jonathan E. Rosenberg, MD, discusses the phase 3 KEYNOTE-045 trial in advanced urothelial cancer.

May 22, 2020

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

May 21, 2020

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.